Douglas Flora: AI in Precision Oncology call for papers
Douglas Flora shared a post on LinkedIn:
“Artificial Intelligence (AI) in Precision Oncology Call for Papers!
Our August issue is off to production, now collecting manuscripts for October and December issues. We are especially interested in original research or reviews and anything out there you’ve been considering writing on AI Ethics and Regulation special issue planning underway.
The editorial team of AI in Precision Oncology invites you to submit your best work for publication!
AI in Precision Oncology is the only peer-reviewed journal dedicated to advancing artificial intelligence applications in clinical and precision oncology. Supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field.
Expansive in scope and mission, AI in Precision Oncology commits to offering every opportunity to researchers in the field by considering a variety of contributions, from research and review papers to commentaries, short reports, mini-reviews, clinical case reports, technical case studies, and Letters to the Editor.
Journal coverage includes:
- AI algorithms for cancer detection, diagnosis, and prognosis.
- AI-based biomarkers for cancer screening and diagnosis.
- AI-assisted imaging analysis for tumor detection and segmentation.
- AI-guided treatment planning and personalized therapy.
- AI-enabled drug discovery and development.
- Machine learning and deep learning in cancer research.
- Natural language processing for electronic health record analysis.
- Ethical and regulatory issues in AI in oncology.
We are eager to consider your research and look forward to your submission!”
Additional information
Source: Douglas Flora/LinkedIn
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.